April 16–April 30, 2018
---
1. The WHO Reaches Out
On a crisp Geneva morning, the headquarters of the World Health Organization buzzed with an urgency it had not felt in years. Normally, WHO summits dealt with bureaucratic minutiae — vaccine quotas, sanitation reports, global obesity studies. But today, every delegate had only one name on their lips:
Sanjeevani Pharma.
In Delhi, Sanjeev Rawat — the humanoid CEO — received the official communiqué on Bharat Mail's diplomatic channel. Arya decrypted and displayed it for Deepak.
> "To Mr. Sanjeev Rawat,
The World Health Organization formally invites Sanjeevani Pharma to join discussions on global licensing, distribution frameworks, and international collaborations. Your breakthroughs represent the single greatest medical advancement in living memory. We look forward to your participation in Geneva, April 25th."
Deepak leaned back in his leather chair, eyes narrowing.
> "So the gatekeepers are opening the door. But they don't want to welcome us in — they want to chain us once we step inside."
Arya's hologram flickered above the table, her voice sharp:
> "They'll dress it as partnership. In reality, it's containment."
---
2. The Curtain Behind the Stage
In a private lounge in Brussels, pharmaceutical CEOs, EU trade commissioners, and lobbyists gathered under low light. Glasses of wine clinked, but the mood was grim.
One CEO slammed the table, his knuckles white.
> "Do you realize what this Sanjeevani cure means? Our cancer division is gone. Years of R&D, $70 billion in projected revenue — wiped out in a month!"
A French commissioner replied coldly:
> "Gentlemen, and ladies, calm yourselves. The WHO is bringing them in. Once inside, we ensure licensing regulations choke their global expansion. Patent wars. Safety certifications. Delays. By the time their drugs reach Europe, the panic will be over."
Across the Atlantic, in Washington, lobbyists drafted memos overnight. One was blunt:
"Objective: Prevent Sanjeevani from obtaining international licenses. Strategy: Overwhelm with compliance barriers and legal pressure. Fallback: Covert destabilization."
---
3. POV – Sanjeev Rawat in Geneva
April 25, Geneva. The air was crisp, Lake Geneva glittering under the spring sun. Black cars lined up outside WHO headquarters as ministers, scientists, and journalists swarmed the complex.
Sanjeev Rawat stepped out in a perfectly tailored suit, every movement smooth yet convincingly human. Cameras flashed like lightning. For the world, he wasn't just a CEO — he was the embodiment of hope.
Inside the assembly, the WHO Director-General greeted him warmly.
> "Mr. Rawat, welcome. The world needs miracles, and Sanjeevani has given us one. Let us discuss how to share it responsibly."
Sanjeev's synthetic eyes scanned the room. His voice carried both gravity and compassion:
> "Sanjeevani does not seek profit. We seek lives saved. But understand this — access will not be controlled by those who put money before survival. Our system, through Bharat Mail and Saraswati Search, ensures fairness. Every patient, regardless of wealth, has the same chance to apply."
Gasps echoed. Delegates whispered nervously. For decades, medicine had been funneled through governments and corporations. Here was a company bypassing both — speaking of direct-to-humanity distribution.
---
4. Behind the Curtain: Lobby Pressure
Even as applause broke out in the hall, backroom phones rang nonstop.
In Washington, pharma lobbyists pushed senators to demand WHO block Sanjeevani until "independent trials" were conducted — trials designed to take 10+ years.
In Berlin, EU regulators drafted a 400-page "compliance framework" overnight, filled with impossible requirements.
In London, newspapers suddenly ran op-eds questioning if Sanjeevani cures were "too good to be true."
The Western establishment wasn't waiting. They were already moving their pieces.
---
5. Deepak's Hidden View
Back in Delhi, Deepak watched the live WHO session on a private feed. Arya overlaid financial charts in real time:
Big Pharma stock collapse so far: $280 billion wiped from global valuations.
Short positions held by Arya: Realized profit now $91 billion USD.
New user surge:
Saraswati Search: 3.1 billion active monthly users.
Bharat Mail: 1.7 billion accounts.
Arya's voice purred with quiet satisfaction:
> "Every attempt to block us only drives people further into our ecosystem. Fear of scarcity creates demand. They cannot stop this tide, Deepak."
Deepak smiled faintly, sipping his tea.
> "And yet, they will try. And their desperation will reveal their weakness."
---
6. Side POV – An African Delegate
In the WHO hall, a delegate from Uganda scribbled in his diary:
> "For the first time in years, I see hope not owned by the West. This Sanjeev Rawat speaks of fairness. If they block him, they block us — Africa itself. We must stand with him."
It was subtle, but a shift had begun. The Global South saw in Sanjeevani not just medicine, but liberation from dependency.
---
7. Closing Scene
The chapter ends with Sanjeev Rawat leaving the WHO building, cameras flashing, questions hurled:
"Mr. Rawat! Will Sanjeevani comply with WHO's licensing process?"
"Are you bypassing national governments?"
"Is this an Indian takeover of global healthcare?"
Sanjeev paused on the marble steps, his voice steady:
> "We do not comply with greed. We comply with humanity."
The crowd erupted, reporters shouting louder, while inside, WHO delegates whispered in alarm.
Watching from Delhi, Deepak whispered to Arya:
> "The war has begun. They smiled today, but tomorrow they'll unsheathe their knives."
---